Allergy Therapeutics
plc
("Allergy
Therapeutics" or the "Group")
Director
Resignation
03
April 2024 Allergy Therapeutics
(AIM: AGY), the fully integrated commercial biotechnology company
specialising in allergy vaccines, today announces that Mary Tavener
has resigned as a Non-Executive Director of the Group with
immediate effect.
The Board wishes to thank Mary for
her valued contribution to the Company over five years of
service.
- ENDS
-
For
further information, please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0) 1903 845 820
Panmure Gordon (Nominated Adviser and
Broker)
Emma Earl, Freddy Crossley, Mark
Rogers, Corporate Finance
Rupert Dearden, Corporate
Broking
+44 (0) 20 7886 2500
ICR
Consilium
+44 20 3709 5700
Mary-Jane Elliott / David Daley /
Davide Salvi
allergytherapeutics@consilium-comms.com
About Allergy
Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that
have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
includes vaccines for grass, tree, house dust mite and peanut. For
more information, please see www.allergytherapeutics.com.